Kailera Therapeutics has launched with a $400 million Series A financing to advance a portfolio of next-generation therapies for obesity and related conditions. The company, based in Massachusetts and California, is led by former Cerevel Therapeutics CEO Ron Renaud. In May 2024, Kailera acquired exclusive rights for global development and commercialization of a portfolio of four metabolic disease assets outside of greater China from Jiangsu Hengrui Pharmaceuticals Co., Ltd.
The most advanced program, KAI-9531, is an injectable GLP-1/GIP receptor dual agonist that demonstrated positive results in Phase 2 trials in obesity and type 2 diabetes in China. Kailera is also advancing a diversified pipeline leveraging several mechanisms and routes of delivery, including KAI-7535, a clinical-stage oral small molecule GLP-1 receptor agonist, KAI-9531 formulated as a once-daily oral tablet, and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. The $400 million Series A round was co-led by Atlas Venture, Bain Capital Life Sciences, and RTW Investments, with participation from Lyra Capital.
This substantial investment demonstrates the significant attention and resources being directed towards the development of obesity treatments.
Kailera secures $400M investment
“In this period of rapid innovation in the metabolic space, I believe that Kailera is poised to make an impact beyond the current market leaders,” said Ron Renaud, Chief Executive Officer of Kailera Therapeutics.
With a clinically-advanced, differentiated pipeline, a talented and experienced team with a track record for building companies with lasting impact, and the support of a world-class investor syndicate, we are uniquely positioned to advance innovative therapies that have the potential to meaningfully impact both quality of life and overall health for many people.
Kailera will be competing in an obesity market currently dominated by Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. However, seasoned investors evidently see significant potential in the recently acquired assets. The company also announced several key leadership appointments, including Doug Bakan as Chief Technology Officer, Paul Burgess as Chief Operating Officer and Chief Business Officer, Paula Cloghessy as Chief People Officer, and Scott Wasserman as Chief Medical Officer.
Additionally, John F. Milligan has joined the Board of Directors as Chair. Kailera’s mission is to develop next-generation weight management therapies that give people the power to transform their lives and elevate their overall health.
With its promising start and strong financial backing, Kailera Therapeutics is poised to make a notable impact in the field of obesity treatment.
